ketoconazole and atovaquone

ketoconazole has been researched along with atovaquone in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Bathurst, I; Burrows, JN; Charman, SA; Cross, RM; Flanigan, DL; Fronczek, FR; Guida, WC; Kyle, DE; LaCrue, AN; Maignan, JR; Manetsch, R; Monastyrskyi, A; Mutka, TS; Sáenz, FE; Shackleford, DM; White, KL; Wojtas, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Meyer, C1
Ashton, M; Bergqvist, Y; Björkman, A; Gil, JP; Thapar, MM; Ursing, J1

Reviews

2 review(s) available for ketoconazole and atovaquone

ArticleYear
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for ketoconazole and atovaquone

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
    Journal of medicinal chemistry, 2014, Nov-13, Volume: 57, Issue:21

    Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Parasitemia; Plasmodium; Plasmodium berghei; Quinolones; Structure-Activity Relationship

2014
Drugs for AIDS and associated infections.
    The Medical letter on drugs and therapeutics, 1995, Oct-13, Volume: 37, Issue:959

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine

1995
A banner year for AIDS therapy.
    The American journal of nursing, 1993, Volume: 93, Issue:5

    Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Antitubercular Agents; Atovaquone; HIV Infections; Humans; Itraconazole; Ketoconazole; Naphthoquinones; Rifabutin; Rifamycins; United States; United States Food and Drug Administration; Zalcitabine

1993
Ketoconazole increases atovaquone exposure following concomitant administration with Malarone® in healthy subjects.
    Journal of travel medicine, 2022, 07-14, Volume: 29, Issue:4

    Topics: Antimalarials; Atovaquone; Drug Combinations; Healthy Volunteers; Humans; Ketoconazole; Malaria, Falciparum; Proguanil

2022